As of Apr 28
| +0.50 / +1.04%|
The 13 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 59.00, with a high estimate of 89.00 and a low estimate of 38.00. The median estimate represents a +21.52% increase from the last price of 48.55.
The current consensus among 14 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.